SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F23%3A00133599" target="_blank" >RIV/00216224:14110/23:00133599 - isvavai.cz</a>
Výsledek na webu
<a href="https://www.jiaci.org/summary/vol33-issue3-num2707" target="_blank" >https://www.jiaci.org/summary/vol33-issue3-num2707</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.18176/jiaci.0845" target="_blank" >10.18176/jiaci.0845</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report
Popis výsledku v původním jazyce
Systemic mastocytosis (SM) is a rare hematological disease characterized by neoplastic proliferation of clonal mast cells (MCs). It involves the gastrointestinal tract, bone, liver, and spleen in addition to bone marrow and skin. The symptoms caused by release of MC mediators and organ infiltration can seriously affect quality of life and survival. Patients with SM are not expected to have a higher risk of infection by SARS-CoV-2; however, this risk can be augmented by comorbidities and impairment of organ function due to infiltration by MCs. Treatment of SM is based on different classes of drugs, which may have an impact on outcome in SARS-CoV-2 infection. However, no study has reported the determinants of outcomes in patients with SM and SARS-CoV-2 infection, according to concurrent treatment.
Název v anglickém jazyce
SARS-CoV-2 Infection In Patients With Mastocytosis: An EPICOVIDEHA Report
Popis výsledku anglicky
Systemic mastocytosis (SM) is a rare hematological disease characterized by neoplastic proliferation of clonal mast cells (MCs). It involves the gastrointestinal tract, bone, liver, and spleen in addition to bone marrow and skin. The symptoms caused by release of MC mediators and organ infiltration can seriously affect quality of life and survival. Patients with SM are not expected to have a higher risk of infection by SARS-CoV-2; however, this risk can be augmented by comorbidities and impairment of organ function due to infiltration by MCs. Treatment of SM is based on different classes of drugs, which may have an impact on outcome in SARS-CoV-2 infection. However, no study has reported the determinants of outcomes in patients with SM and SARS-CoV-2 infection, according to concurrent treatment.
Klasifikace
Druh
J<sub>SC</sub> - Článek v periodiku v databázi SCOPUS
CEP obor
—
OECD FORD obor
30205 - Hematology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2023
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Journal of Investigational Allergology and Clinical Immunology
ISSN
1018-9068
e-ISSN
1698-0808
Svazek periodika
33
Číslo periodika v rámci svazku
3
Stát vydavatele periodika
ES - Španělské království
Počet stran výsledku
3
Strana od-do
225-227
Kód UT WoS článku
001021377800007
EID výsledku v databázi Scopus
2-s2.0-85163311229